Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings I

Webcast link can be found under Investor Relations/Events section of Arcturus’ website.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current a

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being high

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc

Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization

Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about the

Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines compan

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consid

Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing righ

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasd

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with

The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a l

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript

Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger R

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Cons

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the an

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Compa

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Compa

Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ: AR

Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on

Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference

Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analyst

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has earned an average rating of

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analy

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:AR

Citigroup analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lower

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overwei

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits__________________________From time to

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overwei

HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the an